Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Current management of hepatitis C virus infection in patients with HIV co-infection.

Sulkowski MS.

J Infect Dis. 2013 Mar;207 Suppl 1:S26-32. doi: 10.1093/infdis/jis764.

2.

Hepatitis C virus-human immunodeficiency virus coinfection.

Sulkowski MS.

Liver Int. 2012 Feb;32 Suppl 1:129-34. doi: 10.1111/j.1478-3231.2011.02719.x. Review.

PMID:
22212583
3.

A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.

Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.

J Infect Chemother. 2014 May;20(5):320-4. doi: 10.1016/j.jiac.2013.11.006. Epub 2014 Jan 27.

PMID:
24477330
4.

Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.

Beste LA, Green PK, Ioannou GN.

Eur J Gastroenterol Hepatol. 2015 Feb;27(2):123-9. doi: 10.1097/MEG.0000000000000241.

PMID:
25503739
5.

Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

Naggie S, Sulkowski MS.

Gastroenterology. 2012 May;142(6):1324-1334.e3. doi: 10.1053/j.gastro.2012.02.012. Review.

6.
7.

HCV therapy in HIV-infected patients.

Sulkowski MS.

Liver Int. 2013 Feb;33 Suppl 1:63-7. doi: 10.1111/liv.12082. Review.

PMID:
23286848
8.

Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.

Mandorfer M, Payer BA, Niederecker A, Lang G, Aichelburg MC, Strassl R, Boesecke C, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T.

AIDS Patient Care STDS. 2014 May;28(5):221-7. doi: 10.1089/apc.2013.0359.

PMID:
24796757
9.

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA.

PLoS One. 2016 Jan 11;11(1):e0145409. doi: 10.1371/journal.pone.0145409. eCollection 2016.

10.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
11.

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.

Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D; ESCMID European Study Group on Viral Hepatitis.

Liver Int. 2015 Sep;35(9):2090-9. doi: 10.1111/liv.12799. Epub 2015 Feb 23.

PMID:
25650873
12.

Optimizing treatment in HIV/HCV coinfection.

Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, Cocca G, Orso M, Moioli MC.

Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S355-62. doi: 10.1016/j.dld.2013.09.001. Review.

PMID:
24091116
13.

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.

Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serrão R, Sola R, Bertasso A, Passe And S, Stancic S.

HIV Clin Trials. 2012 May-Jun;13(3):142-52. doi: 10.1310/hct1303-142.

PMID:
22592094
14.

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.

AIDS. 2015 Jan 2;29(1):53-8. doi: 10.1097/QAD.0000000000000516.

PMID:
25387314
15.

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.

Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659. Epub 2014 Aug 18.

PMID:
25139963
16.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators.

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

PMID:
23768747
17.

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.

Dieterich D, Nelson M, Soriano V, Arastéh K, Guardiola JM, Rockstroh JK, Bhagani S, Laguno M, Tural C, Ingiliz P, Jain MK, Stern JO, Manero M, Vinisko R, Kort J; STARTVerso4 study group.

AIDS. 2015 Mar 13;29(5):571-81. doi: 10.1097/QAD.0000000000000579.

PMID:
25710287
18.

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.

Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group.

HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11.

19.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Butt AA, Kanwal F.

Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7. Review.

PMID:
22156853
20.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

Supplemental Content

Support Center